The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk—A Systematic Review and Meta Analysis
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prior systematic reviews and meta-analyses of olezarsen in hypertriglyceridemic or dyslipidemic cohorts were limited by small sample sizes, underpowered individual endpoints, lack of restriction to severe hypertriglyceridemia, and absence of systematic evaluation of pancreatitis as a clinical outcome.
“Prior systematic reviews and meta-analyses have reported the efficacy of olezarsen in hypertriglyceridemic or dyslipidemic cohorts; however, these studies were limited by small sample sizes, underpowered individual endpoints, lack of restriction to SHTG, and the absence of systematic evaluation of pancreatitis as a clinical outcome [10][11][12][13].”
From Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2026) · cites this paper as [12]
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Marston, N. A., Giugliano, R. P., Im, K., Silverman, M. G., O’Donoghue, M. L., Wiviott, S. D., Ference, B. A., & Sabatine, M. S. (2019) · Circulation · doi:10.1161/circulationaha.119.041998 · Cited by 301
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400201 · Cited by 271
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402309 · Cited by 214
Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48
Flagged first, then by citations
Research works printed but not linked: 5
- Merkel, 2022, [Triglycerides - assessment as risk factor and therapeutic goals], Dtsch Med Wochenschr, 147, 1286
- Laufs, 2020, Clinical review on triglycerides, Eur Heart J., 41, 99, 10.1093/eurheartj/ehz785 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Tardif, 2022, Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk, Eur Heart J., 43, 1401, 10.1093/eurheartj/ehab820 · DOI · Paper page
- Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy, N Engl J Med., 365, 2255, 10.1056/NEJMoa1107579 · DOI · Paper page
Cited by
Sorted by citations
Rehman, A., Rajdeep, D., Mohnkern, J. D., & Lin, J. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09846-1 · Cited by 2
Metadata
- Authors
- Raja, A., Shafique, M. A., Raja, S., Mustafa, M. S., Shuja, M. H., Ahmed, M., Alim Ur Rahman, H., & Asghar, M. S.
- Affiliations
- Department of Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan
- Jinnah Sindh Medical University (PK)
- Dow University of Health Sciences (PK)
- Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
- Mayo Clinic (US)
- ORCID
- Venue
- American Journal of Therapeutics
- Published
- 2024-12-31
- Volume
- 32
- Issue
- 6
- Pages
- e574-e577
- ISSN
- 1075-2765 (ISSN-L)
- 1536-3686
- OpenAlex
- W4406009684
- Cited by
- 1
- References
- 9
- Citations by year
- 2026: 1
- FWCI
- 0.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Keywords
- olezarsen, hypertriglyceridemia, high cardiovascular risk, triglyceride-lowering therapy, PCSK9 inhibition, cardiovascular risk reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
